![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
New in @OncLive | @eaonc's #EA6194 study | Neoadjuvant Vidutolimod + Pembrolizumab Displays High pCR Rates in Resectable #Melanoma | data presented at @ASCO #ASCO25 by @ATarhiniMDPhD | supported by ā¦@theNCI
ā©
via @onclive
Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma
Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.
www.onclive.com
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: https://bit.ly/ea2222-pump cc : @michael_lidsky
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
38
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
